Cambridge Heart Receives FDA Concurrence for New MTWA Device

Cambridge Heart announced that it has received clearance from the FDA to begin marketing in the U.S. its new Heartwave II System for the measurement of Microvolt T-Wave Alternans (MTWA). Product availability is immediate. The Heartwave II System is a stand-alone device to measure Microvolt T-Wave Alternans to help predict an individual's risk of sudden cardiac death.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050411005944&newsLang=en)